Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors
Lung cancer is a malignant tumor with high incidence rate and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common malignancy. The traditional treatment of NSCLC mainly depends on chemical drugs. In recent years, immunotherapy has become a hot spot in the treatment of NSCLC and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Medical Journal of Peking Union Medical College Hospital
2023-03-01
|
| Series: | Xiehe Yixue Zazhi |
| Subjects: | |
| Online Access: | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2022-0151 |
| _version_ | 1797851426103230464 |
|---|---|
| author | WANG Shuo DENG Yuntian PENG Huan ZHANG Xiangfeng |
| author_facet | WANG Shuo DENG Yuntian PENG Huan ZHANG Xiangfeng |
| author_sort | WANG Shuo |
| collection | DOAJ |
| description | Lung cancer is a malignant tumor with high incidence rate and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common malignancy. The traditional treatment of NSCLC mainly depends on chemical drugs. In recent years, immunotherapy has become a hot spot in the treatment of NSCLC and made remarkable progress. The overall objective remission rate of immunotherapy for NSCLC patients is about 20%. A large number of new biological immune agents have been developed and applied in clinic. Among them, immune checkpoint inhibitor (ICI) has the widest application and the most positive effect on NSCLC. This paper summarizes the research status and progress of immunotherapy biomarkers of NSCLC in recent years, with the hope of improving the accuracy of immunotherapy and better guiding individualized treatment of NSCLC patients. |
| first_indexed | 2024-04-09T19:16:43Z |
| format | Article |
| id | doaj.art-4747435c7e144e01b162b9f65454d50d |
| institution | Directory Open Access Journal |
| issn | 1674-9081 |
| language | zho |
| last_indexed | 2024-04-09T19:16:43Z |
| publishDate | 2023-03-01 |
| publisher | Editorial Office of Medical Journal of Peking Union Medical College Hospital |
| record_format | Article |
| series | Xiehe Yixue Zazhi |
| spelling | doaj.art-4747435c7e144e01b162b9f65454d50d2023-04-06T02:24:19ZzhoEditorial Office of Medical Journal of Peking Union Medical College HospitalXiehe Yixue Zazhi1674-90812023-03-0114240941510.12290/xhyxzz.2022-0151Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint InhibitorsWANG Shuo0DENG Yuntian1PENG Huan2ZHANG Xiangfeng3First Clinical College, Chongqing Medical University, Chongqing 400016, ChinaFirst Clinical College, Chongqing Medical University, Chongqing 400016, ChinaFirst Clinical College, Chongqing Medical University, Chongqing 400016, ChinaPulmonary and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, ChinaLung cancer is a malignant tumor with high incidence rate and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common malignancy. The traditional treatment of NSCLC mainly depends on chemical drugs. In recent years, immunotherapy has become a hot spot in the treatment of NSCLC and made remarkable progress. The overall objective remission rate of immunotherapy for NSCLC patients is about 20%. A large number of new biological immune agents have been developed and applied in clinic. Among them, immune checkpoint inhibitor (ICI) has the widest application and the most positive effect on NSCLC. This paper summarizes the research status and progress of immunotherapy biomarkers of NSCLC in recent years, with the hope of improving the accuracy of immunotherapy and better guiding individualized treatment of NSCLC patients.https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2022-0151non-small cell lung cancerimmunotherapyctla-4pd-1pd-l1 |
| spellingShingle | WANG Shuo DENG Yuntian PENG Huan ZHANG Xiangfeng Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors Xiehe Yixue Zazhi non-small cell lung cancer immunotherapy ctla-4 pd-1 pd-l1 |
| title | Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors |
| title_full | Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors |
| title_fullStr | Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors |
| title_full_unstemmed | Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors |
| title_short | Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors |
| title_sort | progress in the treatment of non small cell lung cancer with immune checkpoint inhibitors |
| topic | non-small cell lung cancer immunotherapy ctla-4 pd-1 pd-l1 |
| url | https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2022-0151 |
| work_keys_str_mv | AT wangshuo progressinthetreatmentofnonsmallcelllungcancerwithimmunecheckpointinhibitors AT dengyuntian progressinthetreatmentofnonsmallcelllungcancerwithimmunecheckpointinhibitors AT penghuan progressinthetreatmentofnonsmallcelllungcancerwithimmunecheckpointinhibitors AT zhangxiangfeng progressinthetreatmentofnonsmallcelllungcancerwithimmunecheckpointinhibitors |